Stem cell source, CD34+ dose and outcomes in haploidentical hematopoietic cell transplantation for myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT

Tomasz Czerw, Luuk Gras, Laurien GA Baaij, Massimiliano Gambella, Didier Blaise, Patrizia Chiusolo, Mi Kwon, Jakob Passweg, Alessandro Busca, Sandrine Loron, Patrice Ceballos, Mohamad Mohty, Fabio Ciceri, Radovan Vrhovac, Antonio Bianchessi, Matteo Parma, Hakan Ozdogu, Johannes Clausen, Linda Koster, Joanna Drozd-Sokolowska, Kavita Raj, Giorgia Battipaglia, Nicola Polverelli, Donal P. McLornan, Juan Carlos Hernández-Boluda
Bone Marrow Transplantation · Springer Nature · 2026-11-17 · DOI: 10.1038/s41409-026-03018-5

Аннотация

Bone Marrow Transplantation, Published online: 17 November 2026; doi:10.1038/s41409-026-03018-5 Stem cell source, CD34+ dose and outcomes in haploidentical hematopoietic cell transplantation for myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT

Читать у издателя →

Похожие статьи